Molecular pathways for immune recognition of preproinsulin signal peptide in type 1 diabetes

Diabetes

Volumn 67, Issue 4, 2018, Pages 687-696

  Kronenberg Versteeg, Deborah ^a,b   Eichmann, Martin ^a   Russell, Mark A ^a,c   Ru, Arnoud De ^d   Hehn, Beate ^e   Yusuf, Norkhairin ^a   Veelen, Peter A Van ^d   Richardson, Sarah J ^c   Morgan, Noel G ^c   Lemberg, Marius K ^e   Peakman, Mark ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; PREPROINSULIN; SIGNAL PEPTIDE; AMINOPEPTIDASE; ASPARTIC PROTEINASE; EPITOPE; ERAP1 PROTEIN, HUMAN; HLA A ANTIGEN; HLA A11 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA-A*02:01 ANTIGEN; HLA-A*11:01 ANTIGEN; HLA-A*24:02 ANTIGEN; INSULIN; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN PRECURSOR; SIGNAL PEPTIDE PEPTIDASE;

ALLELE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CLINICAL ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; ENDOPLASMIC RETICULUM MEMBRANE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; CELL LINE; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; GENE KNOCKOUT; GENETIC PREDISPOSITION; IMMUNOLOGY; METABOLISM; PROTECTION; PROTEIN TRANSPORT; RISK FACTOR;

AMINOPEPTIDASES; ASPARTIC ACID ENDOPEPTIDASES; CELL LINE; DIABETES MELLITUS, TYPE 1; ENDOPLASMIC RETICULUM; EPITOPES; GENE KNOCKOUT TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; HLA-A ANTIGENS; HLA-A11 ANTIGEN; HLA-A2 ANTIGEN; HLA-A24 ANTIGEN; HLA-B ANTIGENS; HUMANS; IN VITRO TECHNIQUES; INSULIN; MINOR HISTOCOMPATIBILITY ANTIGENS; PROTECTIVE FACTORS; PROTEIN PRECURSORS; PROTEIN SORTING SIGNALS; PROTEIN TRANSPORT; RISK FACTORS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85044439831     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db17-0021     Document Type: Article

References (50)

1. Atkinson MA. The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med 2012;2. pii:a007641
2. DiLorenzo TP, Serreze DV. The good turned ugly: Immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice. Immunol Rev 2005;204:250-263
3. Nejentsev S, Howson JM, Walker NM, et al.; Wellcome Trust Case Control Consortium. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007;450:887-892
4. Kronenberg D, Knight RR, Estorninho M, et al. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill b-cells. Diabetes 2012;61: 1752-1759
5. Luce S, Lemonnier F, Briand JP, et al. Single insulin-specific CD8+ T cells show characteristic gene expression profiles in human type 1 diabetes. Diabetes 2011;60:3289-3299
6. Skowera A, Ellis RJ, Varela-Calvinõ R, et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope [published correction appears in J Clin Invest 2009;119:2844].
7. J Clin Invest 2008;118:3390-3402
8. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009;155:173-181
9. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012;209:51-60
10. Richardson SJ, Rodriguez-Calvo T, Gerling IC, et al. Islet cell hyperexpression of HLA class I antigens: A defining feature in type 1 diabetes. Diabetologia 2016;59: 2448-2458
11. Rigby MR, DiMeglio LA, Rendell MS, et al.; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013;1:284-294
12. Howson JM, Walker NM, Clayton D, Todd JA; Type 1 Diabetes Genetics Consortium. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes Metab 2009;11(Suppl. 1):31-45
13. Valdes AM, Erlich HA, Noble JA. Human leukocyte antigen class I B and C loci contribute to type 1 diabetes (T1D) susceptibility and age at T1D onset. Hum Immunol 2005;66:301-313
14. Townsend A, Bastin J, Gould K, et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 1988;168:1211-1224
15. Chang SC, Momburg F, Bhutani N, Goldberg AL. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc Natl Acad Sci USA 2005;102:17107-17112
16. Spies T, Bresnahan M, Bahram S, et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990;348:744-747
17. Cresswell P. Intracellular surveillance: Controlling the assembly of MHC class I-peptide complexes. Traffic 2000;1:301-305
18. Saric T, Chang SC, Hattori A, et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 2002;3:1169-1176
19. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011;11:823-836
20. Martoglio B, Dobberstein B. Signal sequences: More than just greasy peptides. Trends Cell Biol 1998;8:410-415
21. Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B. Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 2002;296: 2215-2218
22. Lemberg MK, Martoglio B. Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis. Mol Cell 2002;10:735-744
23. Lemberg MK, Bland FA, Weihofen A, Braud VM, Martoglio B. Intramembrane proteolysis of signal peptides: An essential step in the generation of HLA-E epitopes. J Immunol 2001;167:6441-6446
24. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 1992;356:443-446
25. Henderson RA, Michel H, Sakaguchi K, et al. HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation. Science 1992; 255:1264-1266
26. El Hage F, Stroobant V, Vergnon I, et al. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasomeindependent pathway. Proc Natl Acad Sci USA 2008;105:10119-10124
27. Bland FA, Lemberg MK, McMichael AJ, Martoglio B, Braud VM. Requirement of the proteasome for the trimming of signal peptide-derived epitopes presented by the nonclassical major histocompatibility complex class I molecule HLA-E. J Biol Chem 2003;278:33747-33752
28. Meiring HD, van der Heeft E, ten Hove GJ, de Jong APJM. Nanoscale LC-MS(n): Technical design and applications to peptide and protein analysis. J Sep Sci 2002;25: 557-568
29. Stepniak D, Wiesner M, de Ru AH, et al. Large-scale characterization of natural ligands explains the unique gluten-binding properties of HLA-DQ2. J Immunol 2008; 180:3268-3278
30. Knight RR, Kronenberg D, Zhao M, et al. Human b-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes 2013;62:205-213
31. Nilsson IM, von Heijne G. Determination of the distance between the oligosaccharyltransferase active site and the endoplasmic reticulum membrane. J Biol Chem 1993;268:5798-5801
32. Martoglio B, Hauser S, Dobberstein B. Cotranslational translocation of proteins into microsomes derived from the rough endoplasmic reticulum of mammalian cells. In Cell Biology: A Laboratory Handbook. Celis JE, Ed. San Diego, CA, Academic Press, 1998, p. 265-274
33. Weihofen A, Lemberg MK, Ploegh HL, Bogyo M, Martoglio B. Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor. J Biol Chem 2000;275:30951-30956
34. Wiltfang J, Smirnov A, Schnierstein B, et al. Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. Electrophoresis 1997;18:527-532
35. Lemberg MK, Martoglio B. Analysis of polypeptides by sodium dodecyl sulfatepolyacrylamide gel electrophoresis alongside in vitro-generated reference peptides. Anal Biochem 2003;319:327-331
36. Eichmann M, de Ru A, van Veelen PA, Peakman M, Kronenberg-Versteeg D. Identification and characterisation of peptide binding motifs of six autoimmune disease-associated human leukocyte antigen-class I molecules including HLA-B∗39: 06. Tissue Antigens 2014;84:378-388
37. Kovjazin R, Volovitz I, Daon Y, et al. Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: Implications for vaccine development. Mol Immunol 2011;48:1009-1018
38. Voss M, Schröder B, Fluhrer R. Mechanism, specificity, and physiology of signal peptide peptidase (SPP) and SPP-like proteases. Biochim Biophys Acta 2013;1828: 2828-2839
39. Li SC, Deber CM. A measure of helical propensity for amino acids in membrane environments. Nat Struct Biol 1994;1:368-373
40. Anderson KS, Zeng W, Sasada T, et al. Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunol Immunother 2011;60:857-867
41. Lundh M, Bugliani M, Dahlby T, et al. The immunoproteasome is induced by cytokines and regulates apoptosis in human islets. J Endocrinol 2017;233:369-379
42. Baschal EE, Baker PR, Eyring KR, Siebert JC, Jasinski JM, Eisenbarth GS. The HLA-B 3906 allele imparts a high risk of diabetes only on specific HLA-DR/DQ haplotypes. Diabetologia 2011;54:1702-1709
43. Avci D, Lemberg MK. Clipping or extracting: Two ways to membrane protein degradation. Trends Cell Biol 2015;25:611-622
44. Panagiotopoulos C, Qin H, Tan R, Verchere CB. Identification of a beta-cellspecific HLA class I restricted epitope in type 1 diabetes. Diabetes 2003;52:2647-2651
45. Ouyang Q, Standifer NE, Qin H, et al. Recognition of HLA class I-restricted betacell epitopes in type 1 diabetes. Diabetes 2006;55:3068-3074
46. Johnson AE, van Waes MA. The translocon: A dynamic gateway at the ER membrane. Annu Rev Cell Dev Biol 1999;15:799-842
47. Rapoport TA, Rolls MM, Jungnickel B. Approaching the mechanism of protein transport across the ER membrane. Curr Opin Cell Biol 1996;8:499-504
48. Dalbey RE, Lively MO, Bron S, van Dijl JM. The chemistry and enzymology of the type I signal peptidases. Protein Sci 1997;6:1129-1138
49. Fluhrer R, Martin L, Klier B, et al. The a-helical content of the transmembrane domain of the British dementia protein-2 (Bri2) determines its processing by signal peptide peptidase-like 2b (SPPL2b). J Biol Chem 2012;287:5156-5163
50. Lemberg MK, Martoglio B. On the mechanism of SPP-catalysed intramembrane proteolysis; conformational control of peptide bond hydrolysis in the plane of the membrane. FEBS Lett 2004;564:213-218